← Back to Screener
CytoMed Therapeutics Limited Ordinary Shares (GDTC)
Price$1.02
Favorite Metrics
Price vs S&P 500 (26W)-59.72%
Price vs S&P 500 (4W)-17.68%
Market Capitalization$9.41M
All Metrics
Book Value / Share (Quarterly)$0.49
P/TBV (Annual)5.62x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.28
Price vs S&P 500 (YTD)-28.48%
EPS (TTM)$-0.25
10-Day Avg Trading Volume0.01M
EPS Excl Extra (TTM)$-0.25
EPS (Annual)$-0.17
ROI (Annual)-26.69%
Cash / Share (Quarterly)$0.19
ROA (Last FY)-25.00%
EBITD / Share (TTM)$-0.18
ROE (5Y Avg)-215.73%
Cash Flow / Share (Annual)$-0.29
P/B Ratio2.12x
P/B Ratio (Quarterly)4.62x
Net Income / Employee (Annual)$-0
Net Interest Coverage (TTM)-16.12x
ROA (TTM)-39.86%
EPS Incl Extra (Annual)$-0.17
Current Ratio (Annual)9.89x
Quick Ratio (Quarterly)4.35x
3-Month Avg Trading Volume0.40M
52-Week Price Return-56.84%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.48
P/S Ratio (Annual)218.47x
Asset Turnover (Annual)0.01x
52-Week High$3.68
EPS Excl Extra (Annual)$-0.17
CapEx CAGR (5Y)5.02%
26-Week Price Return-50.97%
Quick Ratio (Annual)8.44x
13-Week Price Return8.01%
Total Debt / Equity (Annual)0.05x
Current Ratio (Quarterly)5.81x
Enterprise Value$10.089
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-3628.58%
Cash / Share (Annual)$0.34
3-Month Return Std Dev94.94%
Net Income / Employee (TTM)$-0
ROE (Last FY)-28.07%
Net Interest Coverage (Annual)-16.12x
EPS Basic Excl Extra (Annual)$-0.17
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-0.25
ROI (TTM)-43.04%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$0.61
Price vs S&P 500 (52W)-91.93%
Year-to-Date Return-24.34%
5-Day Price Return4.65%
EPS Normalized (Annual)$-0.17
ROA (5Y Avg)-40.55%
Net Profit Margin (Annual)-3621.15%
Month-to-Date Return1.00%
Cash Flow / Share (TTM)$-0.20
EBITD / Share (Annual)$-0.15
Operating Margin (Annual)-3628.58%
LT Debt / Equity (Annual)0.04x
ROI (5Y Avg)-43.64%
LT Debt / Equity (Quarterly)0.05x
EPS Basic Excl Extra (TTM)$-0.25
P/TBV (Quarterly)4.66x
P/B Ratio (Annual)5.56x
Book Value / Share (Annual)$0.61
Price vs S&P 500 (13W)5.14%
Beta-0.21x
Revenue / Share (TTM)$0.02
ROE (TTM)-45.58%
52-Week Low$0.73
Analyst Recommendations
Apr 2025
May 2025
Jun 2025
Jul 2025
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
GDTCCytoMed Therapeutics Limited Ordinary Shares | — | — | — | — | $1.02 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
CytoMed Therapeutics is a pre-clinical biopharmaceutical company developing cell-based immunotherapies for cancer treatment using proprietary technologies. The company operates two main segments: the development of innate immune and pluripotent stem cell therapies, and the processing and banking of cells, including cord blood-derived therapies. Based in Singapore and Malaysia, the company generates the majority of its revenue from Malaysia.